For instance, pharmacological inhibition of the tyrosine kinase activity of BCR-ABL1 reduces CXCR4, which favors egress of CML LSCs into the blood circulation from the bone marrow niche [98]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.